PT - JOURNAL ARTICLE AU - Dumas, Elise AU - Laot, Lucie AU - Coussy, Florence AU - Rejo, Beatriz Grandal AU - Daoud, Eric AU - Laas, Enora AU - Kassara, Amyn AU - Majdling, Alena AU - Kabirian, Rayan AU - Jochum, Floriane AU - Gougis, Paul AU - Michel, Sophie AU - Houzard, Sophie AU - Le Bihan-Benjamin, Christine AU - Bousquet, Philippe-Jean AU - Hotton, Judicaël AU - Azencott, Chloé-Agathe AU - Reyal, Fabien AU - Hamy, Anne-Sophie TI - The French Early Breast Cancer Cohort (FRESH): a resource for breast cancer research and evaluations of oncology practices based on the French National Healthcare System Database (SNDS) AID - 10.1101/2022.03.14.22272286 DP - 2022 Jan 01 TA - medRxiv PG - 2022.03.14.22272286 4099 - http://medrxiv.org/content/early/2022/03/14/2022.03.14.22272286.short 4100 - http://medrxiv.org/content/early/2022/03/14/2022.03.14.22272286.full AB - Background Breast cancer (BC) is the most frequent cancer and the leading cause of cancer-related death in women. The French National Cancer Institute has created a national cancer cohort to promote cancer research and improve our understanding of cancer using the National Health Data System (SNDS). This cohort amalgamates all cancer sites, with no detailed separate data for early BC.Objectives We describe the French Early Breast Cancer Cohort (FRESH).Methods All French women aged 18 years or over, with early-stage BC newly diagnosed between January 1, 2011 and December 31, 2017, treated by surgery and registered in the general health insurance coverage plan were included in the cohort. Patients with suspected locoregional or distant metastases at diagnosis were excluded. BC treatments (surgery, chemotherapy, targeted therapy, radiotherapy, endocrine therapy), and diagnostic procedures (biopsy, cytology, imaging) were extracted from hospital discharge reports, outpatient care notes or pharmacy drug delivery data. BC subtype was inferred from the treatments received.Results We included 235,368 patients with early BC in the cohort (median age: 60 years). BC subtype distribution was as follows: luminal (80.2%), triple-negative (TNBC, 9.5%); HER2+ (10.3%), or unidentifiable (n=44,388, 18.9% of the cohort). Most patients underwent radiotherapy (n=200,685, 85.3%) and endocrine therapy (n=165,655, 70.4%), and 38.3% (n=90,252) received chemotherapy. Treatments and care pathways are described.Conclusion The FRESH Cohort is an unprecedented population-based resource facilitating future large-scale real-life studies aiming to improve care pathways and quality of care for BC patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementElise Dumas received a PhD grant from the Ministere de lEnseignement Superieur et de la Recherche et de lInnovation, allocated to Ecole polytechnique (AMX). This study was also funded by Monoprix. The funder was not involved in study design, or in the collection, analysis, and interpretation of data, the writing of this article or the decision to submit it for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted in the framework of a partnership between Institut Curie and the French INCa. It was performed in accordance with institutional and ethical rules concerning research using data from patients. The study was authorized by the French data protection agency (Commission nationale de linformatique et des libert&eacutes CNIL, under registration number 920017). Personal data were kept confidential, for all participants, by pseudoanonymizing the data. Written informed consent from the patients was not required, in accordance with French regulationsI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.